nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—SIGMAR1—amyotrophic lateral sclerosis	0.522	1	CbGaD
Fluvoxamine—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.207	0.691	CbGbCtD
Fluvoxamine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.0922	0.309	CbGbCtD
Fluvoxamine—Embolus—Riluzole—amyotrophic lateral sclerosis	0.00743	0.0433	CcSEcCtD
Fluvoxamine—Psychotic depression—Riluzole—amyotrophic lateral sclerosis	0.00295	0.0172	CcSEcCtD
Fluvoxamine—Biliary colic—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0148	CcSEcCtD
Fluvoxamine—Major depression—Riluzole—amyotrophic lateral sclerosis	0.0023	0.0134	CcSEcCtD
Fluvoxamine—Rheumatoid arthritis—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0119	CcSEcCtD
Fluvoxamine—Tetany—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0111	CcSEcCtD
Fluvoxamine—Trismus—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0108	CcSEcCtD
Fluvoxamine—Hemiplegia—Riluzole—amyotrophic lateral sclerosis	0.00173	0.0101	CcSEcCtD
Fluvoxamine—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00968	CcSEcCtD
Fluvoxamine—Hyperacusis—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00968	CcSEcCtD
Fluvoxamine—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00968	CcSEcCtD
Fluvoxamine—Manic psychosis—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00912	CcSEcCtD
Fluvoxamine—Yawning—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00895	CcSEcCtD
Fluvoxamine—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00879	CcSEcCtD
Fluvoxamine—Paranoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00848	CcSEcCtD
Fluvoxamine—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00848	CcSEcCtD
Fluvoxamine—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00834	CcSEcCtD
Fluvoxamine—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00769	CcSEcCtD
Fluvoxamine—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00769	CcSEcCtD
Fluvoxamine—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00746	CcSEcCtD
Fluvoxamine—Priapism—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00746	CcSEcCtD
Fluvoxamine—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00735	CcSEcCtD
Fluvoxamine—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00735	CcSEcCtD
Fluvoxamine—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00725	CcSEcCtD
Fluvoxamine—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00725	CcSEcCtD
Fluvoxamine—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00714	CcSEcCtD
Fluvoxamine—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00686	CcSEcCtD
Fluvoxamine—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00686	CcSEcCtD
Fluvoxamine—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00659	CcSEcCtD
Fluvoxamine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00651	CcSEcCtD
Fluvoxamine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00635	CcSEcCtD
Fluvoxamine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00635	CcSEcCtD
Fluvoxamine—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00628	CcSEcCtD
Fluvoxamine—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00599	CcSEcCtD
Fluvoxamine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00599	CcSEcCtD
Fluvoxamine—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00593	CcSEcCtD
Fluvoxamine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00586	CcSEcCtD
Fluvoxamine—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.000985	0.00574	CcSEcCtD
Fluvoxamine—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.000985	0.00574	CcSEcCtD
Fluvoxamine—Embolism—Riluzole—amyotrophic lateral sclerosis	0.000964	0.00562	CcSEcCtD
Fluvoxamine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.000955	0.00556	CcSEcCtD
Fluvoxamine—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.000945	0.0055	CcSEcCtD
Fluvoxamine—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.000945	0.0055	CcSEcCtD
Fluvoxamine—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.000917	0.00534	CcSEcCtD
Fluvoxamine—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00529	CcSEcCtD
Fluvoxamine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00529	CcSEcCtD
Fluvoxamine—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00529	CcSEcCtD
Fluvoxamine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.0009	0.00524	CcSEcCtD
Fluvoxamine—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.000891	0.00519	CcSEcCtD
Fluvoxamine—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.000883	0.00514	CcSEcCtD
Fluvoxamine—Ileus—Riluzole—amyotrophic lateral sclerosis	0.000875	0.00509	CcSEcCtD
Fluvoxamine—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.000875	0.00509	CcSEcCtD
Fluvoxamine—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.000875	0.00509	CcSEcCtD
Fluvoxamine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.000875	0.00509	CcSEcCtD
Fluvoxamine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00505	CcSEcCtD
Fluvoxamine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00505	CcSEcCtD
Fluvoxamine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.000859	0.005	CcSEcCtD
Fluvoxamine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.000859	0.005	CcSEcCtD
Fluvoxamine—Mania—Riluzole—amyotrophic lateral sclerosis	0.000851	0.00496	CcSEcCtD
Fluvoxamine—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.000836	0.00487	CcSEcCtD
Fluvoxamine—Stupor—Riluzole—amyotrophic lateral sclerosis	0.000829	0.00483	CcSEcCtD
Fluvoxamine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.000822	0.00479	CcSEcCtD
Fluvoxamine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.000822	0.00479	CcSEcCtD
Fluvoxamine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.000802	0.00467	CcSEcCtD
Fluvoxamine—Abscess—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00456	CcSEcCtD
Fluvoxamine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00448	CcSEcCtD
Fluvoxamine—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.000764	0.00445	CcSEcCtD
Fluvoxamine—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.000747	0.00435	CcSEcCtD
Fluvoxamine—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00073	0.00425	CcSEcCtD
Fluvoxamine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00419	CcSEcCtD
Fluvoxamine—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00071	0.00413	CcSEcCtD
Fluvoxamine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.000705	0.0041	CcSEcCtD
Fluvoxamine—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00407	CcSEcCtD
Fluvoxamine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00069	0.00402	CcSEcCtD
Fluvoxamine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.000685	0.00399	CcSEcCtD
Fluvoxamine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.000681	0.00396	CcSEcCtD
Fluvoxamine—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00394	CcSEcCtD
Fluvoxamine—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00394	CcSEcCtD
Fluvoxamine—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00391	CcSEcCtD
Fluvoxamine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.000667	0.00389	CcSEcCtD
Fluvoxamine—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.000659	0.00384	CcSEcCtD
Fluvoxamine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.000655	0.00381	CcSEcCtD
Fluvoxamine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.000655	0.00381	CcSEcCtD
Fluvoxamine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00369	CcSEcCtD
Fluvoxamine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00063	0.00367	CcSEcCtD
Fluvoxamine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00365	CcSEcCtD
Fluvoxamine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.000619	0.00361	CcSEcCtD
Fluvoxamine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000619	0.00361	CcSEcCtD
Fluvoxamine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.000612	0.00356	CcSEcCtD
Fluvoxamine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000605	0.00352	CcSEcCtD
Fluvoxamine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00348	CcSEcCtD
Fluvoxamine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00348	CcSEcCtD
Fluvoxamine—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00338	CcSEcCtD
Fluvoxamine—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00338	CcSEcCtD
Fluvoxamine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.000569	0.00331	CcSEcCtD
Fluvoxamine—Coma—Riluzole—amyotrophic lateral sclerosis	0.000566	0.00329	CcSEcCtD
Fluvoxamine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00056	0.00326	CcSEcCtD
Fluvoxamine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00056	0.00326	CcSEcCtD
Fluvoxamine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000543	0.00316	CcSEcCtD
Fluvoxamine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.000537	0.00313	CcSEcCtD
Fluvoxamine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.000532	0.0031	CcSEcCtD
Fluvoxamine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.000527	0.00307	CcSEcCtD
Fluvoxamine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000527	0.00307	CcSEcCtD
Fluvoxamine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.000522	0.00304	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000517	0.00301	CcSEcCtD
Fluvoxamine—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.000514	0.00299	CcSEcCtD
Fluvoxamine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000512	0.00298	CcSEcCtD
Fluvoxamine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000502	0.00293	CcSEcCtD
Fluvoxamine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000502	0.00293	CcSEcCtD
Fluvoxamine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.0005	0.00291	CcSEcCtD
Fluvoxamine—Injury—Riluzole—amyotrophic lateral sclerosis	0.000489	0.00285	CcSEcCtD
Fluvoxamine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00282	CcSEcCtD
Fluvoxamine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.000478	0.00279	CcSEcCtD
Fluvoxamine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000478	0.00279	CcSEcCtD
Fluvoxamine—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00277	CcSEcCtD
Fluvoxamine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.000472	0.00275	CcSEcCtD
Fluvoxamine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00272	CcSEcCtD
Fluvoxamine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000462	0.00269	CcSEcCtD
Fluvoxamine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00046	0.00268	CcSEcCtD
Fluvoxamine—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000451	0.00263	CcSEcCtD
Fluvoxamine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00262	CcSEcCtD
Fluvoxamine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00262	CcSEcCtD
Fluvoxamine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00262	CcSEcCtD
Fluvoxamine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.000446	0.0026	CcSEcCtD
Fluvoxamine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00258	CcSEcCtD
Fluvoxamine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00258	CcSEcCtD
Fluvoxamine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.000439	0.00256	CcSEcCtD
Fluvoxamine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00253	CcSEcCtD
Fluvoxamine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00249	CcSEcCtD
Fluvoxamine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00249	CcSEcCtD
Fluvoxamine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000426	0.00248	CcSEcCtD
Fluvoxamine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00246	CcSEcCtD
Fluvoxamine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000418	0.00243	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000415	0.00242	CcSEcCtD
Fluvoxamine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00239	CcSEcCtD
Fluvoxamine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000409	0.00238	CcSEcCtD
Fluvoxamine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000406	0.00236	CcSEcCtD
Fluvoxamine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000398	0.00232	CcSEcCtD
Fluvoxamine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000396	0.00231	CcSEcCtD
Fluvoxamine—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000391	0.00228	CcSEcCtD
Fluvoxamine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00226	CcSEcCtD
Fluvoxamine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00226	CcSEcCtD
Fluvoxamine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00226	CcSEcCtD
Fluvoxamine—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000381	0.00222	CcSEcCtD
Fluvoxamine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000378	0.0022	CcSEcCtD
Fluvoxamine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000374	0.00218	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00217	CcSEcCtD
Fluvoxamine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000363	0.00212	CcSEcCtD
Fluvoxamine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000359	0.00209	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000358	0.00208	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00206	CcSEcCtD
Fluvoxamine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00206	CcSEcCtD
Fluvoxamine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00205	CcSEcCtD
Fluvoxamine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000348	0.00203	CcSEcCtD
Fluvoxamine—Depression—Riluzole—amyotrophic lateral sclerosis	0.000345	0.00201	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00199	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00198	CcSEcCtD
Fluvoxamine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00198	CcSEcCtD
Fluvoxamine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000338	0.00197	CcSEcCtD
Fluvoxamine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000338	0.00197	CcSEcCtD
Fluvoxamine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000337	0.00196	CcSEcCtD
Fluvoxamine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000332	0.00193	CcSEcCtD
Fluvoxamine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00033	0.00192	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000328	0.00191	CcSEcCtD
Fluvoxamine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000327	0.0019	CcSEcCtD
Fluvoxamine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000325	0.00189	CcSEcCtD
Fluvoxamine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00188	CcSEcCtD
Fluvoxamine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000316	0.00184	CcSEcCtD
Fluvoxamine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00182	CcSEcCtD
Fluvoxamine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00182	CcSEcCtD
Fluvoxamine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000311	0.00181	CcSEcCtD
Fluvoxamine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000311	0.00181	CcSEcCtD
Fluvoxamine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000309	0.0018	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000309	0.0018	CcSEcCtD
Fluvoxamine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000309	0.0018	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000307	0.00179	CcSEcCtD
Fluvoxamine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00178	CcSEcCtD
Fluvoxamine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000305	0.00177	CcSEcCtD
Fluvoxamine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000294	0.00171	CcSEcCtD
Fluvoxamine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00169	CcSEcCtD
Fluvoxamine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000289	0.00168	CcSEcCtD
Fluvoxamine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000282	0.00164	CcSEcCtD
Fluvoxamine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000279	0.00162	CcSEcCtD
Fluvoxamine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000278	0.00162	CcSEcCtD
Fluvoxamine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000275	0.0016	CcSEcCtD
Fluvoxamine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000272	0.00159	CcSEcCtD
Fluvoxamine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000271	0.00158	CcSEcCtD
Fluvoxamine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000267	0.00155	CcSEcCtD
Fluvoxamine—Tension—Riluzole—amyotrophic lateral sclerosis	0.000266	0.00155	CcSEcCtD
Fluvoxamine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000265	0.00154	CcSEcCtD
Fluvoxamine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000263	0.00153	CcSEcCtD
Fluvoxamine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000262	0.00152	CcSEcCtD
Fluvoxamine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00026	0.00152	CcSEcCtD
Fluvoxamine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000254	0.00148	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000251	0.00146	CcSEcCtD
Fluvoxamine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00146	CcSEcCtD
Fluvoxamine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000249	0.00145	CcSEcCtD
Fluvoxamine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000247	0.00144	CcSEcCtD
Fluvoxamine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000244	0.00142	CcSEcCtD
Fluvoxamine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000243	0.00142	CcSEcCtD
Fluvoxamine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000243	0.00141	CcSEcCtD
Fluvoxamine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000242	0.00141	CcSEcCtD
Fluvoxamine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000239	0.00139	CcSEcCtD
Fluvoxamine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000238	0.00139	CcSEcCtD
Fluvoxamine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000236	0.00138	CcSEcCtD
Fluvoxamine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000234	0.00137	CcSEcCtD
Fluvoxamine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000234	0.00136	CcSEcCtD
Fluvoxamine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00023	0.00134	CcSEcCtD
Fluvoxamine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00023	0.00134	CcSEcCtD
Fluvoxamine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00023	0.00134	CcSEcCtD
Fluvoxamine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00023	0.00134	CcSEcCtD
Fluvoxamine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000228	0.00133	CcSEcCtD
Fluvoxamine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000225	0.00131	CcSEcCtD
Fluvoxamine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000223	0.0013	CcSEcCtD
Fluvoxamine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000221	0.00129	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000221	0.00129	CcSEcCtD
Fluvoxamine—Infection—Riluzole—amyotrophic lateral sclerosis	0.000219	0.00128	CcSEcCtD
Fluvoxamine—Shock—Riluzole—amyotrophic lateral sclerosis	0.000217	0.00127	CcSEcCtD
Fluvoxamine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000217	0.00126	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000216	0.00126	CcSEcCtD
Fluvoxamine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000216	0.00126	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000214	0.00124	CcSEcCtD
Fluvoxamine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000211	0.00123	CcSEcCtD
Fluvoxamine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000206	0.0012	CcSEcCtD
Fluvoxamine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.000202	0.109	CbGeAlD
Fluvoxamine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000201	0.00117	CcSEcCtD
Fluvoxamine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.0002	0.00116	CcSEcCtD
Fluvoxamine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000198	0.00115	CcSEcCtD
Fluvoxamine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000197	0.00115	CcSEcCtD
Fluvoxamine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000196	0.00114	CcSEcCtD
Fluvoxamine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000194	0.00113	CcSEcCtD
Fluvoxamine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000192	0.00112	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000191	0.00111	CcSEcCtD
Fluvoxamine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00019	0.00111	CcSEcCtD
Fluvoxamine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000189	0.0011	CcSEcCtD
Fluvoxamine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000189	0.0011	CcSEcCtD
Fluvoxamine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000182	0.00106	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000181	0.00105	CcSEcCtD
Fluvoxamine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000175	0.00102	CcSEcCtD
Fluvoxamine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000175	0.00102	CcSEcCtD
Fluvoxamine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000175	0.00102	CcSEcCtD
Fluvoxamine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000163	0.000948	CcSEcCtD
Fluvoxamine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000158	0.000923	CcSEcCtD
Fluvoxamine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000156	0.00091	CcSEcCtD
Fluvoxamine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.000152	0.0813	CbGeAlD
Fluvoxamine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000151	0.00088	CcSEcCtD
Fluvoxamine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000146	0.000851	CcSEcCtD
Fluvoxamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00014	0.000818	CcSEcCtD
Fluvoxamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000139	0.000811	CcSEcCtD
Fluvoxamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000139	0.00081	CcSEcCtD
Fluvoxamine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.000139	0.0745	CbGeAlD
Fluvoxamine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000138	0.000806	CcSEcCtD
Fluvoxamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000131	0.000764	CcSEcCtD
Fluvoxamine—SLC6A3—brainstem—amyotrophic lateral sclerosis	8.68e-05	0.0466	CbGeAlD
Fluvoxamine—SLC6A4—brainstem—amyotrophic lateral sclerosis	7.96e-05	0.0427	CbGeAlD
Fluvoxamine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	6.69e-05	0.0359	CbGeAlD
Fluvoxamine—SIGMAR1—medulla oblongata—amyotrophic lateral sclerosis	5.51e-05	0.0296	CbGeAlD
Fluvoxamine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	5.4e-05	0.029	CbGeAlD
Fluvoxamine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	4.95e-05	0.0266	CbGeAlD
Fluvoxamine—SIGMAR1—spinal cord—amyotrophic lateral sclerosis	4.91e-05	0.0264	CbGeAlD
Fluvoxamine—SLC6A3—nervous system—amyotrophic lateral sclerosis	4.55e-05	0.0244	CbGeAlD
Fluvoxamine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	4.38e-05	0.0235	CbGeAlD
Fluvoxamine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	4.28e-05	0.023	CbGeAlD
Fluvoxamine—SLC6A4—nervous system—amyotrophic lateral sclerosis	4.17e-05	0.0224	CbGeAlD
Fluvoxamine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	4.01e-05	0.0215	CbGeAlD
Fluvoxamine—SIGMAR1—cerebellum—amyotrophic lateral sclerosis	3.9e-05	0.0209	CbGeAlD
Fluvoxamine—CYP2D6—brainstem—amyotrophic lateral sclerosis	3.84e-05	0.0206	CbGeAlD
Fluvoxamine—SLC6A3—brain—amyotrophic lateral sclerosis	3.48e-05	0.0187	CbGeAlD
Fluvoxamine—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	3.38e-05	0.0181	CbGeAlD
Fluvoxamine—SLC6A4—brain—amyotrophic lateral sclerosis	3.19e-05	0.0171	CbGeAlD
Fluvoxamine—SIGMAR1—brain—amyotrophic lateral sclerosis	3.16e-05	0.017	CbGeAlD
Fluvoxamine—CYP2E1—spinal cord—amyotrophic lateral sclerosis	3.01e-05	0.0162	CbGeAlD
Fluvoxamine—ABCB1—embryo—amyotrophic lateral sclerosis	3.01e-05	0.0162	CbGeAlD
Fluvoxamine—CYP1A1—nervous system—amyotrophic lateral sclerosis	2.78e-05	0.0149	CbGeAlD
Fluvoxamine—CYP2B6—nervous system—amyotrophic lateral sclerosis	2.7e-05	0.0145	CbGeAlD
Fluvoxamine—CYP1A1—central nervous system—amyotrophic lateral sclerosis	2.68e-05	0.0144	CbGeAlD
Fluvoxamine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	2.6e-05	0.014	CbGeAlD
Fluvoxamine—CYP2E1—nervous system—amyotrophic lateral sclerosis	2.54e-05	0.0136	CbGeAlD
Fluvoxamine—CYP2E1—central nervous system—amyotrophic lateral sclerosis	2.44e-05	0.0131	CbGeAlD
Fluvoxamine—CYP2E1—cerebellum—amyotrophic lateral sclerosis	2.39e-05	0.0128	CbGeAlD
Fluvoxamine—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	2.19e-05	0.00376	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	2.18e-05	0.00374	CbGpPWpGaD
Fluvoxamine—CYP1A1—brain—amyotrophic lateral sclerosis	2.13e-05	0.0114	CbGeAlD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	2.09e-05	0.0036	CbGpPWpGaD
Fluvoxamine—CYP2B6—brain—amyotrophic lateral sclerosis	2.07e-05	0.0111	CbGeAlD
Fluvoxamine—CYP3A4—nervous system—amyotrophic lateral sclerosis	2.04e-05	0.011	CbGeAlD
Fluvoxamine—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.02e-05	0.00346	CbGpPWpGaD
Fluvoxamine—CYP2D6—nervous system—amyotrophic lateral sclerosis	2.01e-05	0.0108	CbGeAlD
Fluvoxamine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	2e-05	0.00344	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	2e-05	0.00343	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	1.98e-05	0.0034	CbGpPWpGaD
Fluvoxamine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	1.97e-05	0.0106	CbGeAlD
Fluvoxamine—CYP2E1—brain—amyotrophic lateral sclerosis	1.94e-05	0.0104	CbGeAlD
Fluvoxamine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	1.93e-05	0.0104	CbGeAlD
Fluvoxamine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	1.92e-05	0.0103	CbGeAlD
Fluvoxamine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	1.89e-05	0.0102	CbGeAlD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	1.89e-05	0.00325	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.88e-05	0.00323	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	1.86e-05	0.00319	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.84e-05	0.00316	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.82e-05	0.00313	CbGpPWpGaD
Fluvoxamine—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.72e-05	0.00296	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.72e-05	0.00296	CbGpPWpGaD
Fluvoxamine—ABCB1—spinal cord—amyotrophic lateral sclerosis	1.72e-05	0.00921	CbGeAlD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	1.63e-05	0.00279	CbGpPWpGaD
Fluvoxamine—CYP3A7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.6e-05	0.00275	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.6e-05	0.00275	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.58e-05	0.00271	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.56e-05	0.00268	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.54e-05	0.00264	CbGpPWpGaD
Fluvoxamine—CYP2D6—brain—amyotrophic lateral sclerosis	1.54e-05	0.00825	CbGeAlD
Fluvoxamine—CYP1A1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	1.52e-05	0.00261	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.5e-05	0.00258	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	1.5e-05	0.00257	CbGpPWpGaD
Fluvoxamine—ABCB1—nervous system—amyotrophic lateral sclerosis	1.45e-05	0.00776	CbGeAlD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.41e-05	0.00242	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.4e-05	0.00241	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.4e-05	0.00241	CbGpPWpGaD
Fluvoxamine—ABCB1—central nervous system—amyotrophic lateral sclerosis	1.39e-05	0.00747	CbGeAlD
Fluvoxamine—ABCB1—cerebellum—amyotrophic lateral sclerosis	1.36e-05	0.0073	CbGeAlD
Fluvoxamine—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	1.32e-05	0.00227	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.31e-05	0.00225	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	1.3e-05	0.00223	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.28e-05	0.00221	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	1.28e-05	0.0022	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	1.26e-05	0.00217	CbGpPWpGaD
Fluvoxamine—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	1.25e-05	0.00214	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.23e-05	0.00211	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—VAPB—amyotrophic lateral sclerosis	1.23e-05	0.00211	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—TPK1—amyotrophic lateral sclerosis	1.23e-05	0.00211	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.2e-05	0.00207	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	1.2e-05	0.00206	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	1.2e-05	0.00206	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.19e-05	0.00205	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.19e-05	0.00205	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.19e-05	0.00205	CbGpPWpGaD
Fluvoxamine—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	1.19e-05	0.00205	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	1.19e-05	0.00204	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.18e-05	0.00203	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.17e-05	0.00201	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.00199	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.00199	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.14e-05	0.00196	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.14e-05	0.00196	CbGpPWpGaD
Fluvoxamine—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	1.14e-05	0.00195	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.12e-05	0.00193	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—VAPA—amyotrophic lateral sclerosis	1.12e-05	0.00193	CbGpPWpGaD
Fluvoxamine—ABCB1—brain—amyotrophic lateral sclerosis	1.11e-05	0.00593	CbGeAlD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	1.1e-05	0.00188	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.09e-05	0.00188	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	1.08e-05	0.00186	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.08e-05	0.00185	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.06e-05	0.00183	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.04e-05	0.00179	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	1.04e-05	0.00178	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.03e-05	0.00177	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	1.02e-05	0.00175	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	1.02e-05	0.00175	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—FIG4—amyotrophic lateral sclerosis	9.81e-06	0.00168	CbGpPWpGaD
Fluvoxamine—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.71e-06	0.00167	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.59e-06	0.00165	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	9.17e-06	0.00158	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	9.08e-06	0.00156	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	9.08e-06	0.00156	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.95e-06	0.00154	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—TPK1—amyotrophic lateral sclerosis	8.89e-06	0.00153	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—VAPB—amyotrophic lateral sclerosis	8.89e-06	0.00153	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—DAO—amyotrophic lateral sclerosis	8.87e-06	0.00152	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	8.87e-06	0.00152	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	8.87e-06	0.00152	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.83e-06	0.00152	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.44e-06	0.00145	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	8.38e-06	0.00144	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	8.38e-06	0.00144	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	8.3e-06	0.00143	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.23e-06	0.00141	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	8.17e-06	0.0014	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.16e-06	0.0014	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—VAPA—amyotrophic lateral sclerosis	8.13e-06	0.0014	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.12e-06	0.00139	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	8.11e-06	0.00139	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.05e-06	0.00138	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	7.83e-06	0.00134	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.81e-06	0.00134	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	7.73e-06	0.00133	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.72e-06	0.00133	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.69e-06	0.00132	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	7.67e-06	0.00132	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	7.67e-06	0.00132	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.56e-06	0.0013	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.54e-06	0.0013	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	7.38e-06	0.00127	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	7.26e-06	0.00125	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.13e-06	0.00122	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—FIG4—amyotrophic lateral sclerosis	7.11e-06	0.00122	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	7.09e-06	0.00122	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.98e-06	0.0012	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.97e-06	0.0012	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.88e-06	0.00118	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	6.86e-06	0.00118	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	6.86e-06	0.00118	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	6.72e-06	0.00115	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	6.7e-06	0.00115	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.69e-06	0.00115	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.69e-06	0.00115	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	6.64e-06	0.00114	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.57e-06	0.00113	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	6.56e-06	0.00113	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—DAO—amyotrophic lateral sclerosis	6.43e-06	0.0011	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	6.41e-06	0.0011	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.39e-06	0.0011	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	6.31e-06	0.00108	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	6.31e-06	0.00108	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	6.28e-06	0.00108	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	6.27e-06	0.00108	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	6.25e-06	0.00107	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	6.25e-06	0.00107	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	6.21e-06	0.00107	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.12e-06	0.00105	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	6.06e-06	0.00104	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.93e-06	0.00102	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.93e-06	0.00102	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.83e-06	0.001	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.83e-06	0.001	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	5.77e-06	0.000991	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	5.72e-06	0.000982	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.69e-06	0.000977	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	5.48e-06	0.000941	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.38e-06	0.000924	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.36e-06	0.000921	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.35e-06	0.000919	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.34e-06	0.000918	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.34e-06	0.000918	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.32e-06	0.000913	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.31e-06	0.000911	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.29e-06	0.000908	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	5.1e-06	0.000875	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	5.04e-06	0.000866	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	5.02e-06	0.000862	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	5e-06	0.000858	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.98e-06	0.000856	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	4.97e-06	0.000854	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	4.96e-06	0.000851	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.89e-06	0.000839	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.87e-06	0.000836	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	4.86e-06	0.000835	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	4.84e-06	0.000831	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.59e-06	0.000788	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	4.59e-06	0.000788	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	4.56e-06	0.000783	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.54e-06	0.00078	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	4.52e-06	0.000776	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSR—amyotrophic lateral sclerosis	4.5e-06	0.000772	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	4.49e-06	0.00077	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.27e-06	0.000734	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	4.24e-06	0.000728	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	4.16e-06	0.000715	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	4.12e-06	0.000708	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	4.12e-06	0.000708	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.86e-06	0.000663	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.86e-06	0.000663	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.86e-06	0.000663	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.77e-06	0.000648	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	3.77e-06	0.000647	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	3.76e-06	0.000645	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.69e-06	0.000634	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	3.68e-06	0.000632	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.67e-06	0.00063	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.51e-06	0.000602	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.48e-06	0.000598	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	3.47e-06	0.000595	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	3.46e-06	0.000593	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	3.43e-06	0.000588	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	3.38e-06	0.000581	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.3e-06	0.000566	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.28e-06	0.000563	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	3.19e-06	0.000548	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.18e-06	0.000545	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	3.16e-06	0.000543	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.16e-06	0.000542	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.98e-06	0.000512	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.93e-06	0.000503	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.88e-06	0.000494	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	2.85e-06	0.000489	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.78e-06	0.000477	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.74e-06	0.00047	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.7e-06	0.000464	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.62e-06	0.00045	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.6e-06	0.000446	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	2.6e-06	0.000446	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.52e-06	0.000432	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.48e-06	0.000425	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.46e-06	0.000423	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.37e-06	0.000407	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.26e-06	0.000388	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.22e-06	0.000381	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.18e-06	0.000374	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.09e-06	0.000358	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	2.07e-06	0.000356	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.03e-06	0.000348	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.02e-06	0.000348	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.98e-06	0.000341	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.98e-06	0.00034	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.87e-06	0.000321	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.86e-06	0.00032	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.82e-06	0.000313	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.82e-06	0.000312	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.78e-06	0.000306	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.72e-06	0.000295	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.71e-06	0.000294	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.62e-06	0.000279	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	1.53e-06	0.000263	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.53e-06	0.000263	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	1.5e-06	0.000258	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	1.5e-06	0.000257	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.49e-06	0.000257	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.42e-06	0.000244	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.41e-06	0.000243	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.41e-06	0.000242	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.41e-06	0.000242	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.4e-06	0.00024	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.39e-06	0.000238	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.37e-06	0.000236	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.29e-06	0.000222	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.28e-06	0.00022	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.19e-06	0.000205	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	1.16e-06	0.000199	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.13e-06	0.000194	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.1e-06	0.000188	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-06	0.000183	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-06	0.000181	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.05e-06	0.00018	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.03e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.03e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.69e-07	0.000166	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.2e-07	0.000158	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	9.02e-07	0.000155	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.46e-07	0.000145	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.93e-07	0.000136	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.74e-07	0.000133	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.29e-07	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.23e-07	0.000124	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	6.96e-07	0.000119	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.18e-07	0.000106	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.77e-07	8.19e-05	CbGpPWpGaD
